In HIV type 1-infected children cytotoxic T lymphocyte responses are associated with greater reduction of viremia under antiretroviral therapy

AIDS Research and Human Retroviruses

Volumn 21, Issue 8, 2005, Pages 719-727

  Buseyne, Florence ^a   Le Chenadec, Jérême ^b   Burgard, Marianne ^c   Bellal, Nassima ^a   Mayaux, Marie Jeanne ^b   Rouzioux, Christine ^c   Rivière, Yves ^a   Blanche, Stéphane ^d  

^a INSTITUT PASTEUR   (France)

^b BICÊTRE HOSPITAL   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD8 ANTIGEN; GAG PROTEIN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADOLESCENT; AGE; ANTIGEN SPECIFICITY; ARTICLE; CHILD; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG POTENCY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; NONHUMAN; PEDIATRICS; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT OUTCOME; VIREMIA; VIRUS LOAD; VIRUS REPLICATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; DRUG THERAPY, COMBINATION; HIV-1; HUMANS; INFANT; LONGITUDINAL STUDIES; T-LYMPHOCYTES, CYTOTOXIC; VIRAL LOAD; VIREMIA;

EID: 24344510547     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2005.21.719     Document Type: Article

References (51)

1. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New Engl J Med 1998;338:853-860.
2. Jordan R, Gold L, Cummins C, and Hyde C: Systematic review and meta-analysis of evidence for increasing numbers of drugs in antiretroviral combination therapy. Br Med J 2002;324:1-10.
3. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, Monforte AD, et al.: Decline in the AIDS and death rates in the EuroSIDA study: An observational study. Lancet 2003;362:22-29.
4. de Martino M, Tovo PA, Balducci M, Galli L, Gabiano C, Rezza G, et al.: Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. JAMA 2000; 284:190-197.
5. Gortmaker SL, Hughes M, Cervia J, Brady M, Johnson GM, Seage GR, et al.: Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med 2001;345:1522-1528.
6. Faye A, Bertone C, Teglas JP, Chaix ML, Douard D, Firtion G, et al.: Early multitherapy including a protease inhibitor for human immunodeficiency virus type I-infected infants. Pediatr Infect Dis J 2002;21:518-525.
7. Persaud D, Zhou Y, Siliciano JM, and Siliciano RF: Latency in human immunodeficiency virus type I infection: No easy answers. J Virol 2003;77:1659-1665.
8. Yeni PG, Hammer SM, Carpenter CCJ, Cooper DA, Fischl MA, Gatell JM, et al.: Antiretroviral treatment for adult HIV infection in 2002 - updated recommendations of the international AIDS Society-USA panel. JAMA 2002;288:222-235.
9. Oxenius A, Sewell AK, Dawson SJ, Gunthard HF, Fischer M, Gillespie GM, et al.: Functional discrepancies in HIV-specific CD8+ T-lymphocyte populations are related to plasma virus load. J Clin Immunol 2002;22:363-374.
10. Saag MS: The impact of highly active antiretroviral therapy on HIV-specific immune function. AIDS 2001;15:S4-S10.
11. Dalod M, Harzic M, Pellegrin I, Dumon B, Hoen B, Sereni D, et al.: Evolution of cytotoxic T lymphocyte responses to human immunodeficiency virus type I in patients with symptomatic primary infection receiving antiretroviral triple therapy. J Infect Dis 1998; 178:61-69.
12. Pontesilli O, Kerkhof-Garde S, Notermans DW, Foudraine NA, Roos MTL, Klein MR, et al.: Functional T cell reconstitution and human immunodeficiency virus-1-specific cell-mediated immunity during highly active antiretroviral therapy. J Infect Dis 1999;180: 76-86.
13. Markowitz M, Vesanen M, Tenner-Racz K, Cao YZ, Binley JM, Talal A, et al.: The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses. J Infect Dis 1999;179:527-537.
14. Malhotra U, Berrey MM, Huang YJ, Markee J, Brown DJ, Ap S, et al.: Effect of combination antiretroviral therapy on T-cell immunity in acute human immunodeficiency virus type 1 infection. J Infect Dis 2000;181:121-131.
15. Seth A, Markee J, Hoering A, Sevin A, Sabath DE, Schmitz RE, et al.: Alterations in T cell phenotype and human immunodeficiency virus type 1-specific cytotoxicity after potent antiretroviral therapy. J Infect Dis 2001;183:722-729.
16. Gamberg J, Barrett L, Bowmer MI, Howley C, and Grant M: Factors related to loss of HIV-specific cytotoxic T lymphocyte activity. AIDS 2004;18:597-604.
17. Wherry EJ and Ahmed R: Memory CD8 T-cell differentiation during viral infection. J Virol 2004;78:5535-5545.
18. Russell RR, Bowmer MI, Nguyen C, and Grant MD: HIV-1 DNA burden in peripheral blood CD4+ cells influences disease progression, antiretroviral efficacy, and CD4+ T-cell restoration. Viral Immunol 2001;14:379-389.
19. Mildwan D, Bosch RJ, Kim RS, Spritzler J, Haas DW, Kuritzkes D, et al.: Immunophenotypic markers and antiretroviral therapy (IMART): T cell activation and maturation help predict treatment response. J Infect Dis 2004;189:1811-1820.
20. Clerici M, Saresella M, Trabattoni D, Ferrante P, Vanzulli A, and Vigano A: Thymic volume predicts long-term immune reconstitution in HIV-infected children treated with highly active antiretroviral therapy. AIDS 2002;16:2219-2221.
21. Ruiz-Mateos E, Rubio A, Vallejo A, De la Rosa R, Sanchez-Quijano A, Lissen E, et al.: Thymic volume is associated independently with the magnitude of short- and long-term repopulation of CD4+ T cells in HIV-infected adults after highly active antiretroviral therapy (HAART). Clin Exp Immunol 2004;136:501-506.
22. Ruiz-Mateos E, de la Rosa R, Franco JM, Martinez-Moya M, Rubio A, Soriano N, et al.: Endogenous IL-7 is associated with increased thymic volume in adult HIV-infected patients under highly active antiretroviral therapy. AIDS 2003;17:947-954.
23. Malhotra U, Holte S, Dutta S, Berrey MM, Delpit E, Koelle DM, et al: Role for HLA class II molecules in HIV-1 suppression and cellular immunity following antiretroviral treatment. J Clin Invest 2001;107:505-517.
24. Mohm JM, Rump JA, Schulte-Monting J, and Schneider J: Prognostic value of proliferative responses to HIV-1 antigen in chronically HIV-infected patients under antiretroviral therapy. J Clin Virol 2004;30:239-242.
25. Fernandez-Cruz E, Moreno S, Navarro J, Clotet B, Bouza E, Carbone J, et al.: Therapeutic immunization with an inactivated HIV-1 immunogen plus antiretrovirals versus antiretroviral therapy alone in asymptomatic HIV-infected subjects. Vaccine 2004;22: 2966-2973.
26. Deeks SG, Martin JN, Sinclair E, Harris J, Neilands TB, Maecker HT, et al.: Strong cell-mediated immune responses are associated with the maintenance of low-level viremia in antiretroviral-treated individuals with drug-resistant human immunodeficiency virus type 1. J Infect Dis 2004;189:312-321.
27. Buseyne F, Burgard M, Teglas JP, Bui E, Rouzioux C, Mayaux MJ, et al.: Early human immunodeficiency virus (HIV)-specific cytotoxic T lymphocytes (CTL) and disease progression in children born to HIV-infected mothers. AIDS Res Hum Retroviruses 1998;14:1435-1444.
28. Buseyne F, Le Chenadec J, Corre B, Porrot F, Burgard M, Rouzioux C, et al.: Inverse correlation between memory Gag-specific cytotoxic T lymphocytes and viral replication in human immunodeficiency virus-infected children. J Infect Dis 2002;186: 1589-1596.
29. Buseyne F, Blanche S, Schmitt D, Griscelli C, and Rivière Y: Detection of HIV-specific cell-mediated cytotoxicity in the peripheral blood from infected children. J Immunol 1993;150:3569-3581.
30. Scott-Algara D, Buseyne F, Blanche S, Rouzioux C, Jouanne C, Romagné F, et al.: Frequency and phenotyping of human immunodeficiency virus (HIV)-specific CD8+ T cells in HIV-infected children, using major histocompatibility complex class I peptide tetramers. J Infect Dis 2001;183:1565-1573.
31. Buseyne F, Scott-Algara D, Porrot F, Corre B, Bellal N, Burgard M, et al.: Frequencies of ex vivo-activated human immunodeficiency virus type 1-specific gamma-interferon-producing CD8+ T cells in infected children correlate positively with plasma viral load. J Virol 2002;76:12414-12422.
32. Luzuriaga K, McManus M, Catalina M, Mayack S, Sharkey M, Stevenson M, et al.: Early therapy of vertical human immunodeficiency virus type 1 (HIV-1) infection: Control of viral replication and absence of persistent HIV-1-specific immune responses. J Virol 2000;74:6984-6991.
33. Buseyne F, Chaix ML, Fleury B, Manigard O, Burgard M, Blanche S, et al.: Cross-clade-specific cytotoxic T lymphocytes in HTV-1 infected children. Virology 1998;250:316-324.
34. Lubaki NM, Shepherd ME, Brookmeyer RS, Hon H, Quinn TC, Kashamuka M, et al.: HIV-1-specific cytolytic T-lymphocyte activity correlates with lower viral load, higher CD4 count, and CD8+CD38-DR- phenotype: Comparison of statistical methods for measurement. J Aquir Immune Defic Syndr 1999;22:19-30.
35. Conover WJ: Practical Nonparametric Statistics, 3rd ed. John Wiley & Sons, New York, 1999.
36. Van Rompay KKA, Singh RP, Pahar B, Sodora DL, Wingfield C, Lawson JR, et al.: CD8+-cell-mediated suppression of virulent simian immunodeficiency virus during tenofovir treatment. J Virol 2004;78:5324-5337.
37. Hazuda DJ, Young SD, Guare JP, Anthony NJ, Gomez RP, Wai JS, et al.: Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques. Science, 2004;305: 528-532.
38. Resino S, Bellon JM, Sanchez-Ramon S, Gurbindo D, Leon JA, and Munoz-Fernandez MA: CD8+T-cell numbers predict the response to antiviral therapy in HIV-1-infected children. Pediatr Res 2003;53:309-312.
39. Le Moing V, Chene G, Carrieri MP, Alioum A, Brun-Vezinet F, Piroth L, et al.: Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen. AIDS 2002;16:21-29.
40. Miller V, Staszewski S, Sabin C, Carlebach A, Rottmann C, Weidmann E, et al.: CD4 lymphocyte count as a predictor of the duration of highly active antiretroviral therapy-induced suppression of human immunodeficiency virus load. J Infect Dis 1999;180: 530-533.
41. Spiegel HML, DeFalcon E, Ogg GS, Larsson M, Beadle TJ, Tao P, et al.: Changes in frequency of HIV-1-specific cytotoxic T cell precursors and circulating effectors after combination antiretroviral therapy in children. J Infect Dis 1999;180:359-368.
42. Chitnis V, Pahwa R, and Pahwa S: Determinants of HIV-specific CD8 T-cell responses in HIV-infected pediatric patients and enhancement of HIV-gag-specific responses with exogenous IL-15. Clin Immunol 2003;107:36-45.
43. Sufka SA, Ferrari G, Gryszowka VE, Wrin T, Fiscus SA, Tomaras GD, et al.: Prolonged CD4+ cell/virus load discordance during treatment with protease inhibitor-based highly active antiretroviral therapy: Immune response and viral control. J Infect Dis 2003; 187:1027-1037.
44. Price DA, Scullard G, Oxenius A, Braganza R, Beddows SA, Kazmi S, et al.: Discordant outcomes following failure of antiretroviral therapy are associated with substantial differences in human immunodeficiency virus-specific cellular immunity. J Virol 2003;77:6041-6049.
45. Gea-Banacloche JC, Migueles SA, Martino L, Shupert WL, McNeil AC, Sabbaghian MS, et al.: Maintenance of large numbers of virus-specific CD8+ T cells in HIV-infected progressors and long-term nonprogressors. J Immunol 2000;165:1082-1092.
46. Cao JH, McNevin J, Holte S, Fink L, Corey L, and McElrath AJ: Comprehensive analysis of human immunodeficiency virus type 1 (HIV-1)-specific gamma interferon-secreting CD8+ T cells in primary HIV-1 infection. J Virol 2003;77:6867-6878.
47. Addo MM, Yu XG, Rathod A, Cohen D, Eldridge RL, Strick D, et al.: Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J Virol 2003; 77:2081-2092.
48. Betts MR, Ambrozak DR, Douek DC, Bonhoeffer S, Brenchley JM, Casazza JP, et al.: Analysis of total human immunodeficiency virus (HIV)-specific CD4+ and CD8+ T-cell responses: Relationship to viral load in untreated HIV infection. J Virol 2001;75: 11983-11991.
49. Masemola A, Mashishi T, Khoury G, Mohube P, Mokgotho P, Vardas E, et al.: Hierarchical targeting of subtype C human immunodeficiency virus type 1 proteins by CD8(+) T cells: Correlation with viral load. J Virol 2004;78:3233-3243.
50. Edwards BH, Bansal A, Sabbaj S, Bakari J, Mulligan MJ, and Goepfert PA: Magnitude of functional CD8+ T-cell responses to the Gag protein of human immunodeficiency virus type 1 correlates inversely with viral load in plasma. J Virol 2002;76:2298-2305.
51. Migueles SA, Laborico AC, Shupert WL, Sabbaghian MS, Rabin R, Hallahan CW, et al.: HIV-specific CD8+ T cell proliferation is coupled to perform expression and is maintained in nonprogressors. Nat Immunol 2002;3:1061-1068.